Source - LSE Regulatory
RNS Number : 4256T
MGC Pharmaceuticals Limited
24 November 2021
 

MGC Pharmaceuticals Ltd.

PDMR Notification

24 November 2021

ASX, LSE: MXC

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that the Announcement found at the URL below was released on the ASX Market Announcements Platform today. This Announcement details the recent conversion of Performance Rights in the Company by MGC Pharma Non-Executive Director Ross Walker, and is made in accordance with ASX Listing Rules, and for the purpose of notifying the market of transaction by persons discharging managerial responsibilities (PDMR) in accordance with UK Market Abuse Regulations.

 

A copy of the ASX Announcement can be found at the following URL:

https://www.asx.com.au/asxpdf/20211124/pdf/453c6q8drny8mq.pdf 

 

--Ends--

Authorised for release by the Chairman, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au

MGC Pharmaceuticals Ltd

David Lim

Company Secretary

+61 8 6382 3390

info@mgcpharma.com.au  

UK Broker - Turner Pope

Andy Thacker

+44 203 657 0050

info@turnerpope.com

UK PR Advisors - Tavistock

Charles Vivian / Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGLBDBXUDDGBS
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Mgc Pharmaceuticals Limited (MXC)

+0.10p (+0.48%)
delayed 16:57PM